Adastra Holdings Ltd.

XTRX

CA00654D1006

Pharmaceuticals

Market Closed - Canadian Securities Exchange Other stock markets 12:18:33 01/06/2024 am IST			5-day change	1st Jan Change
0.21 ^CAD	+5.00%		+7.69%	-4.55%

24/04	Adastra Holdings Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
15/04	Adastra Holdings Ltd. Announces Appointment of Lachlan Mcleod as Interim Chief Executive Officer	CI

Adastra Holdings Ltd. Provides Monthly Sales Guidance by July 2022

September 20, 2021 at 06:45 pm IST

Adastra Holdings Ltd. provided monthly sales guidance by July 2022. The Company expects $5 million in monthly sales by July 2022.

Latest news about Adastra Holdings Ltd.

Adastra Holdings Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	24/04	CI
Adastra Holdings Ltd. Announces Appointment of Lachlan Mcleod as Interim Chief Executive Officer	16/04	CI
Adastra Holdings Ltd. Announces Resignation of Smoke Wallin from Its Board of Directors	16/04	CI
Adastra Holdings Announces Executive Changes	03/04	CI
Adastra Holdings Ltd. Appoints Andrew Hale, MBA, BSAE, PMP to its Board of Directors	15/03	CI
Adastra Holdings Ltd. Announces Record Total Purchase Orders Received in January and February	15/03	CI
Adastra Holdings Ltd. Announces Resignation of Michael Forbes as Director and Corporate Secretary, Effective March 29, 2024	02/03	CI
Adastra Holdings Ltd. Announces Resignation of Michael Forbes as CEO, Effective March 29, 2024	02/03	CI
Adastra Holdings Ltd. Receives Purchase Order from the Alberta Gaming, Liquor & Cannabis	02/03	CI
Adastra Holdings Brief: Announcing it has received a Purchase Order for C$1,047,439 from Alberta Gaming, Liquor & Cannabis	02/03	MT
XORTX Therapeutics Brief: Says Submitted a New Patent for the Treatment of Chronic Kidney Disease	03/01	MT
Adastra Holdings Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	30/11	CI
Adastra Holdings Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	17/23/17	CI
XORTX Therapeutics Announces PKD Presentation	06/23/06	MT
Adastra Holdings Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	31/23/31	CI
Adastra Holdings Ltd. Auditor Raises 'Going Concern' Doubt	01/23/01	CI
Adastra Holdings Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	01/23/01	CI
Adastra Brief: Engageing Hybrid Brand Management to expand sales coverage and product sell-through in BC, AB, SK, MB and ON	16/23/16	MT
Adastra Brief: Reporting 152% increase in shipment volume for the first two months of 2023 over the monthly average shipments of 2022	16/23/16	MT
Adastra Brief: Citing Record shipment volume of 379,343 grams and 1,300+ orders during January and February 2023	16/23/16	MT
Adastra Brief: Says To Defend Lawsuit Alleging Co "Misstated Certain Material Facts"; Currently, No Specific Amount of Damages Is Claimed"	16/23/16	MT
Adastra Labs "Clarifies and Retracts" Certain Disclosure Related to its Receipt of Health Canada Approval for Amendment to Include Cocaine Under its Controlled Substances Licence	04/23/04	MT
Adastra Labs Receives Health Canada OK for Amendment to Include Cocaine Under its Controlled Substances Dealer's License	23/23/23	MT
Adastra Labs Receives Health Canada Approval for the Amendment to Include Cocaine Under its Controlled Substances Dealer’s License	23/23/23	CI
Adastra Completes Transaction to Terminate Legacy Supply Agreement, Bringing Phyto Extractions Brand 100% In-House	16/23/16	CI

Adastra Holdings Ltd. is a Canada-based company, which is engaged in the supply and manufacturing of ethnobotanical and cannabis products. The Company serves medical markets and is engaged in therapeutic applications. The Companyâs Phyto Extractions and Endgame Extracts brands distribute cannabis concentrate products through retailers at approximately 2,000 locations across Canada. As a Health Canada licensed facility, it specializes in extraction, distillation and manufacturing of a range of cannabis-derived products. It partners with healthcare professionals and practitioners within the regulated environment to create products suitable for the medical cannabis market. Its subsidiaries include Adastra Labs Holdings (2019) Ltd., Adastra Labs Inc., 1178562 B.C. Ltd., Adastra Brands Inc., Chemia Analytics Inc., 1225140 B.C. Ltd and 1204581 B.C. Ltd.

Sector

Pharmaceuticals

Calendar

03/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Alternative Medicine

	1st Jan change	Capi.
ADASTRA HOLDINGS LTD.	-4.55%	86.15L
DONG-E-E-JIAO CO.,LTD.	+37.29%	602.09Cr
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-21.28%	418.94Cr
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+4.52%	325.49Cr
TASLY PHARMACEUTICAL GROUP CO., LTD	-18.16%	287.36Cr
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-7.70%	237.49Cr
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+41.50%	188.52Cr
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-4.05%	157.98Cr
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-15.56%	154.04Cr
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-14.62%	150.16Cr